Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Meriofert Set, a gonadotropin preparation, is used in fertility treatment pathways to induce and support ovarian follicle development.

• Anovulatory infertility: promotes follicular growth and induces ovulation in women who do not ovulate spontaneously.
• Assisted reproductive technology cycles: enables controlled ovarian hyperstimulation for in‑vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
• Polycystic ovary syndrome (PCOS): facilitates regular ovulation when standard ovulation induction fails.
• Hypogonadotropic hypogonadism: supplies exogenous gonadotropins to support follicular development in patients with deficient endogenous FSH/LH.

• Follicle‑Stimulating Hormone and Luteinising Hormone in Meriofert Set bind to their respective receptors on ovarian granulosa and theca cells. Activation of the FSH receptor stimulates granulosa cell proliferation, aromatase activity and estradiol synthesis, while LH receptor activation triggers theca cell androgen production and final maturation of the dominant follicle. The coordinated signaling cascade leads to follicular growth, estradiol rise, and ultimately ovulation.

Adverse reactions to Meriofert Set may vary in frequency and severity.

Common Side Effects

• Injection site pain, erythema, or swelling at the subcutaneous injection site.
• Abdominal bloating, mild discomfort, or pelvic pressure during follicular development.
• Nausea, headache, or transient fatigue reported after dosing.
• Mild transient increase in estradiol levels causing temporary tenderness.

Serious or Rare Side Effects

• Severe ovarian hyperstimulation syndrome, which may cause ascites, thrombosis, or renal impairment.
• Multiple pregnancy (twins or higher-order) resulting from excessive follicular response.
• Allergic reaction or anaphylaxis presenting with rash, swelling, or respiratory distress.

When using Meriofert Set, careful monitoring and patient assessment are essential.

• Assess ovarian response with ultrasound before each dose.
• Monitor serum estradiol levels during stimulation cycles.
• Avoid use in patients with uncontrolled thyroid or adrenal disorders.
• Use caution in individuals with a history of thromboembolic events.
• Discontinue if signs of severe ovarian hyperstimulation appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other medications; awareness of major and moderate interactions helps ensure safety.

Major Interactions (Avoid)

• Concomitant hCG administration may markedly increase risk of ovarian hyperstimulation syndrome.
• Use with estrogen‑containing contraceptives can blunt the ovarian response.
• Co‑administration with dopamine agonists may reduce gonadotropin efficacy.

Moderate Interactions (Monitor Closely)

• Anticoagulant therapy may increase bleeding risk at injection sites.
• Simultaneous use of other fertility drugs can amplify ovarian response, requiring dose adjustment.
• Thyroid hormone replacement may affect ovarian sensitivity and should be monitored.